Vicuron Pharmaceuticals Inc.

Protagonist Therapeutics, Inc.

Miikana Therapeutics, Inc.

Inipharm, Inc.

Pfizer Corporation

Sampath Kumar Anandan

Dinesh Vinoobhai Patel

Mikhail Fedorovich Gordeev

Jason G Lewis

David Y Liu

John S Ward

Xiao-Yi Xiao

Ashok Bhandari

Brian Troy Frederick

Gregory Thomas Bourne

Larry C Mattheakis

Athisayamani Jeyaraj Duraiswamy

Jie Zhang

Subramanyam Janardhan Tantry

Hardwin O'Dowd

Heather Kay Webb Hsu

Joshua Odingo

Vincent Florio

Liansheng Li

Jason Gustaf Lewis

Mukund M Mehrotra

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).

Dichlorophenol HSD17B13 inhibitors and uses thereof

The invention is directed to opioid agonist peptides and their use.

Opioid agonist peptides and uses thereof

Disclosed are compounds of formula I that inhibit histone deacetylase (HDAC) enzymatic activity, pharmaceutical compositions comprising such compounds, as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC, wherein A, W, W, W, Ar, and G are described herein. 

Inhibitors of histone deacetylase

Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

Lincomycin derivatives possessing antibacterial activity

Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC.

Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against bacteria, including gram positive organisms, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

Growing community of inventors

Fremont, CA, United States of America

Sampath Kumar Anandan